EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical Characteristics and Prognosis of Secondary Acute Lymphoblastic Leukemia in Patients with Multiple Myeloma during Long-Term Thalidomide Maintenance

Junru Liu iD, Beihui Huang, Jingli Gu, Juan Li

Journal of Personalized Medicine · 25.02.2023 · 13 (3) · 412

DOI: 10.3390/jpm13030412 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Personalized Medicine, online erschienen am 25.02.2023. Verfasst von Junru Liu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Secondary primary malignancies (SPM) have attracted increasing attention with the application of autologous hematopoietic stem cell transplantation (ASCT) and novel agents in multiple myeloma (MM). Secondary acute lymphoblastic leukemia (sALL) has rarely been reported, and the clinical characteristics and prognosis of sALL have not been described in detail.

Methods

We retrospectively enrolled 179 consecutive newly diagnosed multiple myeloma (NDMM) patients undergoing bortezomib-based induction regimens followed by upfront ASCT and maintenance therapy from December 2006 to April 2018 in our center.

Results

The median follow-up interval was 69.1 months, and 12 patients (6.7%) developed sALL during maintenance therapy. The median time from the diagnosis of MM to the occurrence of sALL was 51.1 (31.7–91.5) months. All sALL patients received thalidomide as maintenance therapy before the onset of sALL, and the median duration of thalidomide maintenance was 39.5 (24–74) months. The cumulative incidence of sALL was 6.6% and 11.2% at 5 and 10 years after the diagnosis of MM, respectively. All sALL patients presented with a B-cell immunophenotype accompanied by myeloid antigen expression according to flow cytometry analysis, and the BCR/ABL fusion gene was all negative. Only one patient had evidence of active MM, and the other patients were in stable status at the time of the diagnosis of sALL. The prognosis of most sALL patients was very poor, and the median overall survival time was 11.9 (1.1–51.2) months since the diagnosis of sALL. Conclusions: sALL should be considered for MM patients who developed unexplained persistent cytopenia while on long-term thalidomide maintenance treatment, particularly if it has been more than 3 years. With the increasing availability of new drugs for MM, thalidomide may be recommended for no more than 3 years. Sequential allogeneic hematopoietic stem cell transplantation was considered as soon as possible after achieving remission in order to achieve a longer survival.

Schlagwörter

Stichwörter der Autor:innen

acute lymphoblastic leukemiamaintenancemultiple myelomathalidomide

Autor:innen und Institutionen

  • Department of Hematology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China.

ORCID-Profile: Junru Liu

Förderung

  • Natural Science Foundation of Guangdong Province

Zitieren

APA

Liu, J., Huang, B., Gu, J., & Li, J. (2023). Clinical Characteristics and Prognosis of Secondary Acute Lymphoblastic Leukemia in Patients with Multiple Myeloma during Long-Term Thalidomide Maintenance. Journal of Personalized Medicine, 13(3), 412. https://doi.org/10.3390/jpm13030412

Vancouver

Liu J, Huang B, Gu J, Li J. Clinical Characteristics and Prognosis of Secondary Acute Lymphoblastic Leukemia in Patients with Multiple Myeloma during Long-Term Thalidomide Maintenance. Journal of Personalized Medicine. 2023;13(3):412. doi:10.3390/jpm13030412

BibTeX
@article{Liu2023,
  author = {Liu, Junru and Huang, Beihui and Gu, Jingli and Li, Juan},
  title = {Clinical Characteristics and Prognosis of Secondary Acute Lymphoblastic Leukemia in Patients with Multiple Myeloma during Long-Term Thalidomide Maintenance},
  journal = {Journal of Personalized Medicine},
  year = {2023},
  volume = {13},
  number = {3},
  pages = {412},
  doi = {10.3390/jpm13030412}
}
Kostenlos starten →